



Reference list

# CliniMACS® CD34 System

<b>HLA Mismatched Donor and Haploidentical Stem Cell Transplantation</b>	<b>1</b>
<b>HLA Identical Sibling and Matched Unrelated Donor Cell Transplantation</b>	<b>4</b>
<b>CD34<sup>+</sup> Selected Stem Cell Boosts in Allogeneic Transplantation</b>	<b>7</b>
<b>Reduced Intensity or Non-Myeloablative Conditioning and T Cell Depletion</b>	<b>9</b>
<b>Allogeneic Transplantation in Patients with Non-Malignant Diseases</b>	<b>9</b>
<b>Cord Blood Transplantation</b>	<b>11</b>
<b>Tumor Cell Purging in Autologous Transplantation</b>	<b>12</b>
<b>Autologous Transplantation (i.a. Autoimmune Diseases)</b>	<b>13</b>
<b>CliniMACS® Selection Performance</b>	<b>14</b>

## HLA Mismatched Donor and Haploidentical Stem Cell Transplantation

### Health Care Utilization and Cost among Pediatric Patients Receiving Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.

*Bourgeois W, Ricci A, Jin Z, Hall M, George D, Bhatia M, Garvin J, Satwani P.*  
Bone Marrow Transplant 2018, Epub ahead of print.  
<https://doi.org/10.1038/s41409-018-0308-0>.

### Unexpected High Incidence of Human Herpesvirus-6 Encephalitis after Naïve T Cell-Depleted Graft of Haploidentical Stem Cell Transplantation in Pediatric Patients.

*Sisinni L, Gasior M, de Paz, Raquel, Querol S, Bueno D, Fernandez L, Marsal J, Sastre A, Gimeno R, Alonso L, Badell I, Lopez-Granados E, Torres J, Medina L, Torrent M, Diaz de Heredia C, Escudero A, Perez-Martinez A.*  
Biol Blood Marrow Tr. 2018, 24(11):2316-23.

### Advances in Haploidentical Stem Cell Transplantation for Hematologic Malignancies.

*Montoro J, Sanz J, Sanz GF, Sanz MA.*  
Leuk Lymphoma. 2016, 57(8):1766-75.

### Modern Approaches to HLA-Haploidentical Blood or Marrow Transplantation.

*Kanakry CG, Fuchs EJ, Luznik L.*  
Nat Rev Clin Oncol. 2016, 13(1):10-24.

### Treatment of Graft Failure with TNI-based Reconditioning and Haploidentical Stem Cells in Paediatric Patients.

*Teltschik HM, Heinzelmann F, Gruhn B, Feuchtinger T, Schlegel P, Schumm M, Kremens B, Müller I, Ebinger M, Schwarze CP, Ottinger H, Zips D, Handgretinger R, Lang P.*  
Br J Haematol. 2016, 175(1):115-22.

### "Designed" Grafts for HLA-Haploidentical Stem Cell Transplantation.

*Martelli MF, Di Ianni M, Ruggeri L, Pierini A, Falzetti F, Carotti A, Terenzi A, Reisner Y, Aversa F, Falini B, Velardi A.*  
Blood 2014, 123(7):967-73.

### Haploidentical Related-Donor Hematopoietic Cell Transplantation in Children Using Megadoses of CliniMACS-Selected CD34<sup>+</sup> Cells and a Fixed CD3<sup>+</sup> Dose.

*Dvorak CC, Gilman AL, Horn B, Oon C-Y, Dunn EA, Baxter-Lowe LA and Cowan MJ.*  
Bone Marrow Transplant. 2013, 48(4):508-13.

### Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation.

*Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE.*  
Biol Blood Marrow Tr. 2012, 181(2):1835-44.

**Haploidentical Bone Marrow Transplantation in Mexico.**

Vazquez-Meraz JE, Arellano-Galindo J, Mendoza-Garcia E, Jimenez-Hernandez E, Avalos AM, Guadarrama NV, Arangure JMM.  
Pediatr Blood Cancer. 2012, 59(5):950-2.

**T Cell-Depleted Partial Matched Unrelated Donor Transplant for Advanced Myeloid Malignancy: KIR Ligand Mismatch and Outcome**

Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J.  
Biol Blood Marrow Tr. 2012, 18(6):937-43.

**Haploidentical Stem Cell Transplantation for Children with High-Risk Leukemia.**

Palma J, Salas L, Carrión F, Sotomayor C, Catalán P, Paris C, Turner V, Jorquera H, Handgretinger R, Rivera GK.  
Pediatr Blood Cancer. 2012, 59(5):895-901.

**T Cell Depleted Haploidentical Transplantation: Positive Selection.**

Aversa F.  
Pediatr Rep. 2011, 3(S2):e14.

**Haploidentical Hematopoietic Transplantation: Current Status and Future Perspectives.**

Reisner Y, Hagin D, Martelli MF.  
Blood 2011, 118(23):6006-18.

**A 2-Step Approach to Myeloablative Haploidentical Stem Cell Transplantation: A Phase 1/2 Trial Performed with Optimized T-Cell Dosing.**

Grosso D, Carabasi M, Filicko-O'Hara J, Kasner M, Wagner JL, Colombe B, Farley PC, O'Hara W, Flomenberg P, Werner-Wasik M, Brunner J, Mookerjee B, Hyslop T, Weiss M, Flomenberg N.  
Blood 2011, 118(17):4732-9.

**High Success Rate of Hematopoietic Cell Transplantation Regardless of Donor Source in Children with Very High-Risk Leukemia.**

Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz JE, Sandlund JT, Ribeiro RC, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Handgretinger R, Laver JH, Pui CH.  
Blood 2011, 118(2):223-30.

**Tregs Prevent GVHD and Promote Immune Reconstitution in HLA-Haploidentical Transplantation.**

Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF.  
Blood 2011, 117(14):3921-8.

**Natural Killer Cell Activity Influences Outcome after T Cell Depleted Stem Cell Transplantation from Matched Unrelated and Haploidentical Donors.**

Lang P, Pfeiffer M, Teltschik HM, Schlegel P, Feuchtinger T, Ebinger M, Klingebiel T, Bader P, Schlegel PG, Beck J, Greil J, Handgretinger R.  
Best Pract Res Clin Haematol 2011, 24(3):403-11.

**Graft Manipulation and Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation from Mismatched Unrelated and Mismatched/Haploidentical Related Donors in Pediatric Leukemia Patients.**

Gonzalez-Vicent M, Perez A, Abad L, Sevilla J, Ramirez M, Diaz MA.  
J Pediatr Hematol Oncol. 2010, 32(3):85-90.

**Results and Factors Influencing Outcome after Fully Haploidentical Hematopoietic Stem Cell Transplant in Children with Very-High Risk Acute Lymphoblastic Leukemia - Impact of Center Size: An Analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group.**

Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, Balduzzi A, Owoc-Lempach J, Fagioli F, Or R, Peters C, Aversa F, Polge E, Dini G, Rocha V.  
Blood 2010, 115(17):3437-46.

**Retransplantation with Stem Cells from Mismatched Related Donors after Graft Rejection in Pediatric Patients.**

Lang P, Mueller I, Greil J, Bader P, Schumm M, Pfeiffer M, Hoelle W, Klingebiel T, Heinzelmann F, Belka C, Schlegel PG, Kremens B, Woessmann W, Handgretinger R.  
Blood Cells Mol Dis. 2008, 40(1):33-39.

**A Survey of Fully Haploidentical Hematopoietic Stem Cell Transplantation in Adults with High-Risk Acute Leukemia: A Risk Factor Analysis of Outcomes for Patients in Remission at Transplantation.**

Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, Nagler A, Di Bartolomeo P, Lacerda JF, Lupo Stanghellini MT, Polge E, Frassoni F, Martelli MF, Rocha V, on behalf of the Acute Leukemia Working Party (ALWP) of the European Blood and Marrow Transplant (EBMT) Group.  
Blood 2008, 112(9):3574-81.

**The Haploidentical Option for High-Risk Haematological Malignancies.**

Aversa F, Reisner Y, Martelli MF.  
Blood Cells Mol Dis. 2008, 40(1):8-12.

**Donor Natural Killer Cell Allorecognition of Missing Self in Haploidentical Hematopoietic Transplantation for Acute Myeloid Leukemia: Challenging Its Predictive Value.**

Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Vianchi E, Aversa F, Martelli MF, Velardi A.  
Blood 2007, 110(1):433-40.

**Full Haplotype-Mismatched Hematopoietic Stem-Cell Transplantation: A Phase II Study in Patients with Acute Leukemia at High Risk of Relapse.**

Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MF, Mecucci C, Reisner Y, Martelli MF.  
J Clin Oncol. 2005, 23(15):3447-54.

**Long-Term Outcome after Haploidentical Stem Cell Transplantation in Children.**

Lang P, Greil J, Bader P, Handgretinger R, Klingebiel T, Schumm M, Schlegel PG, Feuchtinger T, Pfeiffer M, Scheel-Walter H, Führer M, Martin D, Niethammer D.  
Blood Cells Mol Dis. 2004, 33(3):281-7.

**Fourth International Workshop on Haploidentical Transplants, Naples, Italy, July 8-10, 2004.**

Aversa F, Berneman ZN, Locatelli F, Martelli MF, Reisner Y, Tabilio A, Velardi A, Vuk-Pavlovic S.  
Blood Cells Mol Dis. 2004, 33(3):159-75.

**Hematopoietic Stem Cell Transplantation from Alternative Sources in Adults with High-Risk Acute Leukemia.**

Aversa F, Reisner Y, Martelli MF.  
Blood Cells Mol Dis. 2004, 33(3):294-302.

**Transplantation of Haploidentically Mismatched Stem Cells for the Treatment of Malignant Diseases.**

Aversa F, Martelli MF.  
Springer Semin Immunopathol. 2004, 26(1):155-68.

**Transplantation of a Combination of CD133<sup>+</sup> and CD34<sup>+</sup> Selected Progenitor Cells from Alternative Donors.**

Lang P, Bader P, Schumm M, Feuchtinger T, Einsele H, Führer M, Weinstock C, Handgretinger R, Kuci S, Martin D, Niethammer D, Greil J.  
Br J Haematol. 2004, 124(1):72-9.

**Effective Donor Lymphohematopoietic Reconstitution after Haploidentical CD34<sup>+</sup> Selected Hematopoietic Stem Cell Transplantation in Children with Refractory Severe Aplastic Anemia.**

Woodard P, Cunningham JM, Benaim E, Chen X, Hale G, Horwitz E, Houston J, Kasow K, Leung W, Wang W, Yusuf U, Handgretinger R.  
Bone Marrow Transplant. 2004, 33(4):411-8.

**Megadose Transplantation of Highly Purified Haploidentical Stem Cells: Current Results and Future Prospects.**

Handgretinger R, Klingebiel T, Lang P, Gordon P, Niethammer D.  
Pediatr Transplant. 2003, 7(S3):51-5.

**Haploidentical Stem Cell Transplantation with Purified CD34<sup>+</sup> Cells after a Chemotherapy-Alone Conditioning Regimen.**

Lacerda JF, Martins C, Carmo JA, Lourenco F, Juncal C, Rodrigues A, Vilalobos I, Moura MC, Ligeriro D, Martinho A, Lacerda JMF.  
Biol Blood Marrow Tr. 2003, 9(10):633-42.

**Haploidentical 'Megadose' Stem Cell Transplantation in Acute Leukemia: Recommendations for a Protocol Agreed Upon at the Perugia and Chicago Meetings.**

Champlin R, Hesdorffer C, Lowenberg B, Martelli MF, Mertelsmann RH, Reisner Y, Schmitz N.  
Leukemia. 2002, 16(3):427-8.

**Haploidentical 'Megadose' CD34<sup>+</sup> Cell Transplants for Patients with Acute Leukemia.**

Martelli MF, Reisner Y.  
Leukemia. 2002, 16(3):404-5.

**Megadose Transplantation of Purified Peripheral Blood CD34<sup>+</sup> Progenitor Cells from HLA Mismatched Parental Donors in Children.**

Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A, Bader P, Schlegel PG, Greil J, Stachel D, Herzog RJ, Niethammer D.  
Bone Marrow Transplant. 2001, 27(8):777-83.

**Immunological Aspects of Haploidentical Stem Cell Transplantation in Children.**

Handgretinger R, Lang P, Schumm M, Pfeiffer M, Gottschling S, Demirdelen B, Bader P, Kuci S, Klingebiel T, Niethammer D.  
Ann NY Acad Sci. 2001, 938(1):340-58.

# HLA Identical Sibling and Matched Unrelated Donor Cell Transplantation

## **Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes.**

Huang YT, Su Y, Kim SJ, Nichols P, Burack D, Maloy M, Giralt S, Perales MA, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Tr. 2018, Epub ahead of print. <https://doi.org/10.1016/j.bbmt.2018.11.012>.

## **Favorable Immune Recovery and Low Rate of GVHD in Children Transplanted with Partially T Cell-Depleted PBSC Grafts.**

Seitz CM, Eyrich M, Greil J, Schlegel P, Feuchtinger T, Bader P, Ebinger M, Schwarze CP, Schlegel PG, Schumm M, Handgretinger R, Lang P.

Bone Marrow Transplant. 2019, 54(1):53-62.

## **CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome.**

Barba P, Martino R, Zhou Q, Cho C, Castro-Malaspina H, Devlin S, Esquirol A, Giralt S, Jakubowski AA, Caballero D, Maloy M, Papadopoulos EB, Pinana JL, Fox ML, Marquez-Malaver FJ, Valcarcel D, Solano C, Lopez-Corral L, Sierra J, Perales MA.

Biol Blood Marrow Tr. 2018, 24(5):964-72.

## **Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia.**

Ebens CL, DeFor TE, Tryon R, Wagner JE, MacMillan ML.

Biol Blood Marrow Tr. 2018, 24(4):765-71.

## **Impact of Toxicity on Survival for Older Adult Patients after CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation.**

Shah GL, Scordo M, Kosuri S, Herrera DA, Cho C, Devlin SM, Borrill T, Carlow DC, Vecilla ST, Meagher RC, O'Reilly RJ, Jakubowski AA, Papadopoulos EB, Koehne G, Gyurkocza B, Castro-Malaspina H, Shaffer BC, Perales MA, Giralt SA, Tamari R.

Biol Blood Marrow Tr. 2018, 24(1):142-9.

## **Effects of Late Toxicities on Outcomes in Long-Term Survivors of ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.**

Scordo M, Shah BL, Kosuri S, Herrera DA, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Vecilla ST, Meagher RC, Carlow DC, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Tamari R, Perales MA, Giralt SA, Shaffer BC.

Biol Blood Marrow Tr. 2018, 24(1):133-41.

## **Long-Term Prognosis for 1-Year Relapse-Free Survivors of CD34+ Cell-Selected Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis.**

Cho C, Hsu, M, Barba P, Maloy MA, Vecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, Jakubowski AA, Koehne G, Meagher RC, O'Reilly RJ, Papadopoulos EB, Ponce DM, Tamari R, van den Brink MRM, Young JW, Devlin SM, Perales MA.

Bone Marrow Transplant. 2017, 52(12):1629-36.

## **A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.**

Spitzer B, Jakubowski AA, Papadopoulos EB, Fuller K, Hilden PD, Young JW, Barker JN, Koehne G, Perales MA, Hsu KC, van den Brink MR, Kernan NA, Prockop SE, Scaradavou A, Castro-Malaspina H, O'Reilly RJ, Boulad F.

Biol Blood Marrow Tr. 2017, 23(12):2088-95.

## **Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.**

Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, van den Brink MRM, Young JW, O'Reilly RJ, Giralt SA, Perales MA

Biol Blood Marrow Tr. 2017, 23(1):67-74.

## **Radiation-Free, Alternative-Donor HCT for Fanconi Anemia Patients: Results from a Prospective Multi-Institutional Study.**

Mehta PA, Davies SM, Leemhuis T, Myers K, Keman NA, Prockop SE, Scaradavou A, O'Reilly RJ, Williams DA, Lehmann L, Guinan E, Margolis D, Baker KS, Lane A and Boulad F.

Blood 2017, 129(16):2308-15.

## **Long Term Renal Survival in Patients Undergoing T-Cell Depleted versus Conventional Hematopoietic Stem Cell Transplants.**

Glezerman, IG, Devlin S, Maloy M, Bui M, Jaimes EA, Giralt SA, Jakubowski AA.

Bone Marrow Transplant. 2017, 52(5):733-8.

**The Impact of Toxicities on First-Year Outcomes after *ex vivo* CD34<sup>+</sup> Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies.**

Kosuri S, Herrera DA, Scordo M, Shah GJ, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Carlow DC, AVECILLA ST, Meagher RC, O'Reilly RJ, Papadopoulos ES, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Shaffer BC, Tamari R, Giralt SA, Perales MA.  
Biol Blood Marrow Tr. 2017, 23(11):2004-11.

**T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.**

Jakubowski AA, Petrlik E, Maloy M, Hilden P, Papadopoulos E, Young JW, Boulad F, Castro-Malaspina H, Tamari R, Dahi PB, Goldberg J, Koehne G, Perales MA, Sauter CS, O'Reilly RJ, Giralt S.  
Biol Blood Marrow Tr. 2017, 23(10):1685-94.

**Co-Infections by Double-Stranded DNA Viruses after *ex vivo* T Cell-Depleted, CD34<sup>+</sup> Selected Hematopoietic Cell Transplantation.**

Huang YT, Kim SJ, Lee YJ, Burack D, Nichols P, Maloy M, Perales MA, Giralt SA, Jakubowski AA, Papanicolaou GA.  
Biol Blood Marrow Tr. 2017, 23(10):1759-66.

***Ex vivo* CD34<sup>+</sup> Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.**

Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Prockop S, Sauter C, Tamari R, van den Brink MRM, AVECILLA ST, Meagher R, O'Reilly RJ, Goldberg JD, Young JW, Giralt S, Perales MA, Ponce DM.  
Biol Blood Marrow Tr. 2017, 23(10):452-8.

**Adenovirus Viremia in Adult CD34<sup>+</sup> Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact.**

Lee YJ, Huang YT, Kim SJ, Maloy M, Ramari R, Giralt SA, Papadopoulos EB, Jakubowski AA, Papanicolaou GA.  
Biol Blood Marrow Tr. 2016, 22(1):170-82.

**CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.**

Smith E, Devlin SM, Kosuri S, Orlando E, Landau H, Lesokhin AM, Chung DJ, Hassoun H, Lendvai N, Landgren O, Giralt S, Chari A, Jagannath S, Koehne G.  
Biol Blood Marrow Tr. 2016, 22(2):258-67.

**Long-Term Prognosis Among 1-Year Survivors of *ex vivo* T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis.**

Cho C, Hsu M, AVECILLA S, Barbara P, Barker JN, Castro-Malaspina H, Devlin SM, Giralt SA, Jakubowski AA, Koehne G, Meagher R, O'Reilly RJ, Papadopoulos E, Ponce DM, van den Brink MRM, Young JW, Perales MA.  
Biol Blood Marrow Tr. 2016, 22(3):S84-S85.

**Comparison of Outcomes at Two Institutions of Patients with ALL Receiving *ex vivo* T-Cell-Depleted or Unmodified Allografts.**

Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, Devlin SM, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt S, Perales MA, Kebriaei P.  
Bone Marrow Transplant. 2015, 50(4):493-8.

**CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.**

Tamari R, Chung SS, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, Goldberg JD, Perales MA, Ponce DM, Sauter CS, Maloy MA, Herman DY, Klimek V, Young JW, O'Reilly RJ, Giralt SA, Castro-Malaspina H.  
Biol Blood Marrow Tr. 2015, 21(12):2106-14.

**Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients.**

Hobbs GS, and Perales MA.  
J Clin Med. 2015, 4(3), 488-503.

**Outcomes of Acute Leukemia Patients Transplanted with Naive T Cell-Depleted Stem Cell Grafts.**

Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD.  
J Clin Invest. 2015, 125(7):2677-89.

***Ex vivo* T Cell-Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission.**

Bayraktar UD, De Lima M, Rima SM, Maloy M, Castro-Malaspina H, Chen JJ, Rondon G, Chiattonne A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin R, Giralt SA, Andersson BS, Papadopoulos EB.  
Biol Blood Marrow Tr. 2013, 19(6):898-903.

**T Cell-Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft-versus-Host Disease.**

Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MR, Young JW, Boulad F, Kernan NA, O'Reilly RJ, Prockop SE, Yahalom J, Heller G, and Perales MA.

Biol Blood Marrow Tr. 2013, 19(2):208-13.

**Comparative Outcomes of Donor Graft CD34<sup>+</sup> Selection and Immune Suppressive Therapy as Graft-versus-Host Disease Prophylaxis for Patients with Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation.**

Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, O'Reilly RJ, Robert J, Soiffer RJ.

J Clin Oncol. 2012, 30(26):3194-201.

**T Cell Depletion Utilizing CD34<sup>+</sup> Stem Cell Selection and CD3<sup>+</sup> Addback from Unrelated Adult Donors in Paediatric Allogeneic Stem Cell Transplantation Recipients.**

Geyer MB, Ricci AM, Jacobson JS, Majzner R, Duffy D, Van de Ven C, Ayello J, Bhatia M, Garvin JH Jr, George D, Satwani P, Harrison L, Morris E, Semidei-Pomales M, Schwartz J, Alobeid B, Baxter-Lowe LA, Cairo MS.

Br J Haematol. 2012, 157(2):205-19.

**Long-Term Survival and Late Deaths after Allogeneic Hematopoietic Cell Transplantation.**

Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Horowitz MM, Bolwell B, Rizzo JD, Socie G.

J Clin Oncol. 2011, 29(16):2230-9.

**Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell-Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303.**

Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP, Keever-Taylor CA, O'Reilly RJ.

Biol Blood Marrow Tr. 2011, 17(9):1343-51.

**HLA-Matched Sibling Transplantation with BM and CD34<sup>+</sup>-Purified PBSCs in Adult Patients with High-Risk Severe Aplastic Anemia to Overcome Graft Rejection without an Increase in GVHD.**

Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Min WS, Park CW, Kim CC, Lee JW.

Bone Marrow Transplant. 2010, 45(10):1497-501.

**Comparative Effectiveness Analysis of CD34<sup>+</sup> Selected, T-Cell Depleted (TCD) HLA-Matched Sibling Grafts on Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Acute Myeloid Leukemia (AML) in Complete Remission.**

Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus H, Appelbaum F, Keever-Taylor CA, O'Reilly RJ, Soiffer RJ on behalf of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Biol Blood Marrow Tr. 2010, 16(2):S268 (ASBMT Annual Meeting Abstracts).

**CD34<sup>+</sup> Cell Selection of Peripheral Blood Progenitor Cells Using the CliniMACS Device for Allogeneic Transplantation: Clinical Results in 102 Patients.**

Ringhoffer M, Wiesneth M, von Harsdor S, Schlenk F, Schmitt A, Reinhardt PP, Moessner M, Grimminger W, Mertens T, Reske SN, Döhner H, Bunjes D.

Brit J Haematol. 2004, 126(4):527-35.

**Allogeneic Transplantation of Selected Peripheral CD34<sup>+</sup> Cells with Controlled CD3<sup>+</sup> Cells Addback in High Risk Patients.**

Markiewicz M, Holowiecki J, Wojnar J, Krawczyk-Kulis M, Jagoda K, Giebel S, Kruzel.

Transpl P. 2004, 36(10):3194-9.

**Outcome of Transplantation of Highly Purified Peripheral Blood CD34<sup>+</sup> Cells with T-Cell Addback Compared with Unmanipulated Bone Marrow or Peripheral Blood Stem Cells from HLA Identical Sibling Donors in Patients with First Chronic Phase Chronic Myeloid Leukemia.**

Elmaagacli A, Peceny R, Steckel N, Trenschele R, Ottinger H, Grosse-Wilde H, Schaefer UW, Beelen DW.

Bone Marrow Transplant. 2003, 101(2):446-53.

**Selected CD34 Blood Cell Allografts for Older Patients: Low Transplant-Related Mortality, Graft Failure and Acute GvHD.**

Roberts MM, Dyson P, Rawling C, Thorp D, Rawling T, White D, Horvath N, Bardy P, Hui CH, Dart GW, To LB, Hughes TP.

Cytotherapy 2003, 5(6):534-41.

**Transplantation of Highly Purified CD34<sup>+</sup> Progenitor Cells from Unrelated Donors in Pediatric Leukemia.**

Lang P, Handgretinger R, Niethammer D, Schlegel PG, Schumm M, Greil J, Bader P, Engel C, Scheel-Walter H, Eyrich M, Klingebiel T.

Blood 2003, 101(4):1630-6.

**A Prospective Comparison of Immune Reconstitution in Pediatric Recipients of Positively Selected CD34<sup>+</sup> Peripheral Blood Stem Cells from Unrelated Donors vs Recipients of Unmanipulated Bone Marrow from Related Donors.**

Eyrich M, Leiler C, Lang P, Schilbach K, Schumm M, Bader P, Greil J, Klingebiel T, Handgretinger R, Niethammer D, Schlegel PG.  
Bone Marrow Transplant. 2003, 32(4):379-90.

**Early Lymphocyte Recovery is an Important Determinant of Outcome Following Allogeneic Transplantation with CD34<sup>+</sup> Selected Graft and Limited T-Cell Adbback.**

Chakrabarti S, Brown J, Guttridge M, Pamphilon DH, Lankester A, Marks DI.  
Bone Marrow Transplant. 2003, 32(1):23-30.

**Addition of a Low Fixed Number of CD3<sup>+</sup> Cells to CD34-Enriched Allografts: Effects on Engraftment, Graft-versus-Host Disease, and Survival after Related and Unrelated Peripheral Stem Cell Transplantation.**

Goerner M, Weber-Nordt R, Hoepfner S, Benner A, Luft T, Ho AD.  
J Hematother Stem Cell Res. 2003, 12(3):309-20.

**Positive Selection for CD34<sup>+</sup> Reduces the Incidence and Severity of Venous Occlusive Disease of the Liver after HLA-Identical Sibling Allogeneic Peripheral Blood Stem Cell Transplantation.**

Moscardo F, Urbano-Ispizua A, Sanz GF, Brunet S, Caballero D, Vallejo C, Solano C, Pimentel P, Perez de Oteyza J, Ferra C, Diez-Martin JL, Zuazu J, Espigado I, Campilho F, Arbona C, Moraleda JM, Mateos MV, Sierra J, Talarn C, Sanz MA.  
Exp Hematol. 2003, 31(6):545-50.

**Allogeneic Transplantation of CD34<sup>+</sup>-Selected Cells from Peripheral Blood in Patients with Myeloid Malignancies in Early Phase: A Case Control Comparison with Unmodified Peripheral Blood Transplantation.**

Urbano-Ispizua A, Brunet S, Solano C, Moraleda JM, Rovira M, Zuazu J, de La Rubia J, Bargay J, Caballero D, Diez-Martin JL, Ojeda E, Perez de Oteyza JP, Ferra C, Espigado I, Alegre A, de La Serna J, Torres P, Riu C, Odriozola J, Rozman C, Sierra J, Garcia-Conde J, Montserrat E.  
Spanish Group of Allo-PBT.  
Bone Marrow Transplant. 2001, 28(4):349-54.

**Allogeneic Transplantation of G-CSF Mobilized Peripheral Blood Stem Cells from Unrelated Donors: A Retrospective Analysis.**

Bornhäuser M, Theuser C, Soucek S, Hölig K, Klingebiel T, Blau W, Fauser A, Runde V, Schwinger W, Rutt C, Ehninger G.  
Haematologica 2000, 85(8):839-47.

## CD34<sup>+</sup> Selected Stem Cell Boosts in Allogeneic Transplantation

**Post-Transplant CD34<sup>+</sup> Selected Stem Cell "Boost" for Mixed Chimerism after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Children and Young Adults with Primary Immune Deficiencies.**

Chandra S, Bleesing JJ, Jordan MB, Grimley MS, Khandelwal P, Davies SM, Edwards S, Leemhuis T, Marsh RA.  
Biol Blood Marrow Tr. 2018, 24(7):1527-9.

**CD34<sup>+</sup> Selected Stem Cell Boosts can Improve Poor Graft Function after Paediatric Allogeneic Stem Cell Transplantation.**

Mainardi C, Ebinger M, Enkel S, Feuchtinger T, Teltschik HM, Eyrich M, Schumm M, Rabsteyn A, Schlegel P, Seitz C, Schwarze CP, Müller I, Greil J, Bader P, Schlegel PG, Martin D, Holzer U, Döring M, Handgretinger R, Lang P.  
Br J Haematol. 2018, 180(1):90-9.

**Fresh or Cryopreserved CD34<sup>+</sup> Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation.**

Ghobadi A, Fiala MA, Ramsingh G, Gao F, Abboud CN, Stockerl-Goldstein K, Uy FL, Grossman BJ, Westervelt P, DiPersio JF.  
Biol Blood Marrow Tr. 2017, 23(7):1072-7.

**Poor Graft Function can be Durably and Safely Improved by CD34<sup>+</sup>-Selected Stem Cell Boosts after Allogeneic Unrelated Matched or Mismatched Hematopoietic Cell Transplantation.**

Haen SP, Schumm M, Faul C, Kanz L, Bethge WA, Vogel W.  
J Cancer Res Clin Oncol. 2015, 141(12):2241-51.

**Outcomes of Acute Leukemia Patients Transplanted with Naïve T Cell-Depleted Stem Cell Grafts.**

Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD.  
J Clin Invest. 2015, 125(7):2677-89.

**Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation with a Booster of CD34-Selected Cells Infused without Conditioning.**

Askaa B, Fischer-Nielsen A, Vindeløv L, Haastrup EK, Sengeløv H.  
Bone Marrow Transplant. 2014, 49(5):720-1.

**CD34 Selected Cells for the Treatment of Poor Graft Function after Allogeneic Stem Cell Transplantation.**

*Stasia A, Ghiso A, Galaverna F, Raiola AM, Gualandi F, Luchetti S, Pozzi S, Varaldo R, Lamparelli T, Gregante S, van Lint MT, di Grazia T, Bacigalupo A. Biol Blood Marrow Tr. 2014, 20(9):1440-3.*

**Engineering Human Peripheral Blood Stem Cell Grafts that are Depleted of Naïve T Cells and Retain Functional Pathogen-Specific Memory T Cells.**

*Bleakley M, Heimfeld S, Jones LA, Turtle C, Krause D, Riddell SR, Shlomchik W. Biol Blood Marrow Tr. 2014, 20(5):705-16.*

**CD34<sup>+</sup>-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies.**

*Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, Chabannon C, Crocchiolo R, Lemarié C, Faucher C, Bacher U, Alchalby H, Stübig T, Wolschke C, Ayuk F, Reckhaus ML, Blaise D, Kröger N. Biol Blood Marrow Tr. 2014, 20(3):382-6.*

**CD34<sup>+</sup>-Selected Stem Cell Boost for Delayed or Insufficient Engraftment after Allogeneic Stem Cell Transplantation.**

*Oyekunle A, Koehl U, Schieder H, Ayuk F, Renges H, Fehse N, Zabelina T, Fehse B, Klingebiel T, Sputtek A, Zander A, Kroger N. Cytotherapy 2006, 8(4):375-80.*

**Boost of CD34<sup>+</sup>-Selected Peripheral Blood Cells without Further Conditioning in Patients with Poor Graft Function Following Allogeneic Stem Cell Transplantation.**

*Larocca A, Piaggio G, Podesta M, Pitto A, Bruno B, Di Grazia C, Gualandi F, Occhini D, Raiola AM, Dominietto A, Bregante S, Lamparelli T, Tedone E, Oneto R, Frassoni F, Van Lint MT, Pogliani E, Bacigalupo A. Haematologica 2006, 91(7):935-40.*

**T-Cell-Depleted Stem Cell Boost for the Treatment of Autoimmune Haemolytic Anaemia after T-Cell-Depleted Allogeneic Bone Marrow Transplantation Complicated by Adenovirus Infection.**

*Hilgendorf I, Wolff D, Wilhelm S, Steiner B, Kiefel V, Hickstein H, Junghanss C, Freund M, Casper J. Bone Marrow Transplant. 2006, 37(10):977-8.*

**Outcome of Boost Haematopoietic Stem Cell Transplant for Decreased Donor Chimerism or Graft Dysfunction in Primary Immuno-Deficiency.**

*Slatter MA, Bhattacharya A, Abinun M, Flood TJ, Cant AJ, Gennery AR. Bone Marrow Transplant. 2005, 35(7):683-9.*

**CD34-Enriched Peripheral Stem Cells Infusion for Graft Insufficiency Treatment in a Pediatric Patient with Severe Aplastic Anemia after Allogeneic Bone Marrow Transplantation.**

*Trakhtman P, Shipicina I, Balashov D, Scvortsova J, Dishlevaja Z, Blagonravova O, Maschan A. Bone Marrow Transplant. 2004, 34(5):465-6.*

**Successful Treatment of Primary Refractory Acute Myeloid Leukemia with Megadose Stem Cell Transplantation, Bone Marrow Boost and Reduced Intensity Conditioning Avoiding Chronic Graft vs. Host Disease and Severe Late Toxicity.**

*Langer T, Beck JD, Gravou-Apostulatou C, Lang P, Handgretinger R, Greil J. Pediatr Transplant. 2003, 7(6):494-6.*

**Second Hematopoietic Stem Cell Transplantation for the Treatment of Graft Failure, Graft Rejection or Relapse after Allogeneic Transplantation.**

*Wolff SN. Bone Marrow Transplant. 2002, 29(7):545-52.*

**CD34<sup>+</sup> Immunoselected Cells for Poor Graft Function Following Allogeneic BMT.**

*Mohty M, Faucher C, Chabannon C, Vey N, Stoppa AM, Ladaïque P, Novakovitch G, Olivero S, Bouabdalah R, Gastaut JA, Maraninchi D, Blaise D. Cytotherapy 2000, 2(5):367-70.*



## Reduced Intensity or Non-Myeloablative Conditioning and T Cell Depletion

### **Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.**

Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz, AS.  
Biol Blood Marrow Tr. 2018, 24(5):997-1004.

### **Reduced-Intensity Conditioning Using Fludarabine, Melphalan and Thiotepa for Adult Patients Undergoing Haploidentical SCT.**

Ciurea SO, Saliba R, Rondon G, Pessoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbaling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J  
Bone Marrow Transplant. 2010, 45(3):429-36.

### **T-Cell Depletion does not Necessarily Compromise Donor Stem Cell Engraftment in Patients Receiving Reduced-Intensity Conditioning Regimens.**

Craddock C, Grigg AP.  
Bone Marrow Transplant. 2003, 31(12):1177.

### **Limiting Transplantation-Related Mortality Following Unrelated Donor Stem Cell Transplantation by Using a Nonmyeloablative Conditioning Regimen.**

Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuert S, Geary J, Thuraiyandaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S.  
Blood 2002, 99(3):1071-8.

### **Stable Mixed Chimerism after T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation Using Conditioning with Low-Dose Total Body Irradiation and Fludarabine.**

Goerner M, Kordelas L, Thalheimer M, Preiffer S, Ustaoglu F, Punzel M, Weber-Nordt R, Moos M, Goldschmidt H, Ho AD.  
Bone Marrow Transplant. 2002, 29(7):621-4.

### **Short Report: Engraftment of T-Cell-Depleted Allogeneic Haematopoietic Stem Cells Using a Reduced Intensity Conditioning Regimen.**

Craddock C, Bardy P, Kreiter S, Johnston R, Apperley J, Marks D, Huber C, Kolbe K, Goulding R, Lawler M, Goldman J, Hughes T, Derigs G.  
Br J Haematol. 2000, 111(3):797-800.

## Allogeneic Transplantation in Patients with Non-Malignant Diseases

### **Alternative Donor Hematopoietic Stem Cell Transplantation for Sickle Cell Disease.**

Gilman AL, Eckrich, MJ, Epstein S, Barnhart C, Cannon M, Fukes T, Hyland M, Shah K, Grochowski D, Champoin E, Ivanova A.  
Blood Advances 2017, 1(16):1215-23.

### **T-Cell-Depleted Hematopoietic SCT from Unrelated Donors for the Treatment of Congenital Amegakaryocytic Thrombocytopenia.**

Tarek N, Kernan NA, Prockop SE, Scaradavou A, Small TN, O'Reilly RJ, Boulad F.  
Bone Marrow Transplant. 2012, 47(5):744-6.

### **Successful Second Haploidentical SCT in Osteopetrosis.**

Stepensky P, Schulz AS, Lahr G, Simanovsky N, Brooks R, Samuel S, Or R, Weintraub M, Resnick I.  
Bone Marrow Transplant. 2011, 46(7):1021-2.

### **T Cell-Depleted HLA-Haploidentical Stem Cell Transplantation in Thalassemia Young Patients.**

Sodani P, Isgrò A, Gaziev J, Paciaroni K, Marziali M, Simone MD, Roveda A, De Angelis G, Gallucci C, Torelli F, Isacchi G, Zinno F, Landi F, Adorno G, Lanti A, Testi M, Andreani M, Lucarelli G.  
Pediatr Rep. 2011, 3(S2):e13.

### **Purified T-Depleted, CD34<sup>+</sup> Peripheral Blood and Bone Marrow Cell Transplantation from Haploidentical Mother to Child with Thalassemia.**

Sodani P, Isgrò A, Gaziev J, Polchi P, Paciaroni K, Marziali M, Simone MD, Roveda A, Montuoro A, Alfieri C, De Angelis G, Gallucci C, Erer B, Isacchi G, Zinno F, Adorno G, Lanti A, Faulkner L, Testi M, Andreani M, Lucarelli G.  
Blood 2010, 115(6):1296-302.

### **Immunomagnetic Selection of CD34<sup>+</sup> Cells Carried Out in Cryopreserved Cell Concentrates from a Paediatric Patient Affected with Non-Hodgkin Lymphoma.**

Zinno F, Landi F, Aureli V, Cometa AM, Scerpa MC, Caniglia M, Pinto RM, Rana I, Balduino G, Miele MJ, Isacchi G.  
Transfus Med. 2010, 20(4):283-6.

### **Positive Immunomagnetic CD34<sup>+</sup> Cell Selection in Haplo-Identical Transplants in Betathalassemia Patients: Removal of Platelets Using an Automated System.**

Zinno F, Landi F, Aureli V, Balduino G, Lanti A, Sodani P, Adorno G, Lucarelli G, Isacchi G.  
Cytotherapy 2010, 12(1):60-6.

**Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy.**

*Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefrère F, Blanche S, Audit M, Payen E, Leboulch P, l'Homme B, Bougnères P, Von Kalle C, Fischer A, Cavazzana-Calvo M, Aubourg P.*  
Science 2009, 326(5954):818-23.

**Successful Transplantation of CD34<sup>+</sup> Selected Peripheral Blood Stem Cells from an Unrelated Donor in an Adult Patient with Diamond-Blackfan Anemia and Secondary Hemochromatosis.**

*Berndt A, Helwig A, Ehninger G, Bornhauser M.*  
Bone Marrow Transplant. 2005, 35(1):99-100.

**Transplantation of Highly Purified CD34<sup>+</sup> Progenitor Cells from Alternative Donors in Children with Refractory Severe Aplastic Anemia.**

*Benesch M, Urban C, Sykora KW, Schwinger W, Zintl F, Lackner H, Lang P, Handgretinger R.*  
Br J Haematol. 2004, 125(1):58-63.

**Transplantation of CD34<sup>+</sup> Enriched Allografts in Children with Nonmalignant Diseases: Does Graft Manipulation Necessarily Result in High Incidence of Graft Failure?**

*Lang P, Handgretinger R, Greil J, Bader P, Schumm M, Klingebiel T, Niethammer D.*  
Bone Marrow Transplant. 2004, 33(1):125-6.

**Transplantation of Highly Purified Peripheral-Blood CD34<sup>+</sup> Progenitor Cells from Related and Unrelated Donors in Children with Nonmalignant Diseases.**

*Lang P, Klingebiel T, Bader P, Greil J, Schumm M, Schlegel PG, Eyrych M, Mueller-Wehrich S, Niethammer D, Handgretinger R.*  
Bone Marrow Transplant. 2004, 33(1):25-32.

**Allogeneic Bone Marrow Stem Cell Transplantation Following CD34<sup>+</sup> Immunomagnetic Enrichment in Patients with Inherited Metabolic Storage Diseases.**

*Gaipa G, Dassi M, Perseghin P, Venturi N, Corti P, Bonanomi S, Balduzzi A, Longoni D, Uderzo C, Biondi A, Masera G, Parini R, Bertagnolio B, Uziel G, Peters C, Rovelli A.*  
Bone Marrow Transplant. 2003, 31(10):857-60.

**Successful T-Cell-Depleted, Related Haploidentical Peripheral Blood Stem Cell Transplantation in a Patient with Fanconi Anaemia Using a Fludarabine-based Preparative Regimen without Radiation.**

*Rossi G, Giorgiani G, Comoli P, Nobili B, Salvaneschi L, De Stefano P, Maccario R, Locatelli F.*  
Bone Marrow Transplant. 2003, 31(6):437-40.

**Allogeneic CD34-Selected Peripheral Stem Cell Transplantation from Parental Donors in Children with Non-Malignant Diseases.**

*Kremens B, Basu O, Peceny R, Grosse-Wilde H, Schaefer UW, Havers W.*  
Bone Marrow Transplant. 2002, 29(1):9-13.

**Stem Cell Transplantation for the Treatment of Fanconi Anaemia Using a Fludarabine-based Cytoreductive Regimen and T-Cell-Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Grafts.**

*Boulad F, Gillio A, Small TN, George D, Prasad V, Torok-Castanza J, Regan AD, Collins N, Auerbach AD, Kernan NA, O'Reilly RJ.*  
Br J Haematol. 2000, 111(4):1153-7.

**Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease.**

*Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bouso P, Deist FL, Fischer A.*  
Science 2000, 288(5466):669-72.

**T-Cell-Depleted Peripheral Blood Stem Cell Transplantation for Alpha-Mannosidosis.**

*Albert MH, Schuster F, Peters C, Schulze S, Pontz BF, Muntau AC, Roschinger W, Stachel DK, Enders A, Haas RJ, Schmid I.*  
Bone Marrow Transplant. 2000, 32(4):443-6.

**Successful Haploidentical Bone Marrow Transplantation in Fanconi Anemia.**

*Elhasid R, Ben Arush MW, Katz T, Gan Y, Shechter Y, Sami I, Postovsky S, Reisner Y, Rowe JM.*  
Bone Marrow Transplant. 2000, 26(11):1221-3.

## Cord Blood Transplantation

### **Haploidentical Cord Transplantation - The Best of Both Worlds.**

*van Besien K and Childs R.*

Semin Hematol. 2016, 53(4):257-66.

### **Alternative Donor Transplantation - "Mixing and Matching": The Role of Combined Cord Blood and Haplo-Identical Donor Transplantation (Haplo-Cord SCT) as a Treatment Strategy for Patients Lacking Standard Donors?**

*Liu H and van Besien K.*

Curr Hematol Malig Rep. 2015, 10(1):1-7.

### **Haplo-Cord Transplantation Using CD34<sup>+</sup> Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders.**

*Kwon M, Bautista G, Balsalobre P, Sánchez-Ortega S, Serrano D, Anguita J, Buno I, Fores R, Regidor C, García Marco JA, Vilches C, de Pablo R, Fernandez MN, Gayoso J, Duarte R, Díez-Martín JL, Cabrera R.*  
Biol Blood Marrow Tr. 2014, 20(12):2015-22.

### **Early Engraftment and Full-Donor Chimerism after Single-Cord Blood plus Third-Party Donor Dual Transplantation in Patients with High-Risk Acute Leukemia.**

*Sánchez-Ortega I, Arnan M, Patiño B, Herrero MJ, Querol S, Duarte RF.*

Bone Marrow Transplant. 2014, 49(1):145-7.

### **Early Peripheral Blood and T-Cell Chimerism Dynamics after Umbilical Cord Blood Transplantation Supported with Haploidentical Cells.**

*Kwon M, Martínez-Laperche C, Balsalobre P, Serrano D, Anguita J, Gayoso J, Díez-Martín JL, Buño I.*

Bone Marrow Transplant. 2014, 49(2):212-8.

### **Umbilical Cord Blood Transplantation Supported by Third-Party Donor Cells: Rationale, Results, and Applications.**

*van Besien K, Liu H, Jain N, Stock W, Artz A.*

Biol Blood Marrow Tr. 2013, 19(5):682-91.

### **Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched-Unrelated Donor Transplantation in High-Risk Hematological Patients.**

*Kwon M, Balsalobre P, Serrano D, Corral AP, Buno I, Anguita J, Gayoso J, Díez-Martín JL.*

Biol Blood Marrow Tr. 2013, 19(1):143-9.

### **Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment, Low GVHD and Durable Remissions**

*Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, Artz AS, van Besien K.*

Blood 2011, 118(24):6438-45.

### **Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process.**

*Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, Schaap N, Dolstra H.*  
PLoS One 2011, 6(6):e20740.

### **High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy.**

*Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I, Schaap N, de Witte TM, Dolstra H.*

PLoS One 2010, 5(2):e9221.

### **Improving the Outcome of Cord Blood Transplantation: Use of Mobilized HSC and Other Cells from Third Party Donors.**

*Fernandez MN.*

Br J Haematol. 2009, 147(2):161-76.

### **Cord Blood Transplants Supported by Co-Infusion of Mobilized Hematopoietic Stem Cells from a Third-Party Donor.**

*Bautista G, Cabrera JR, Regidor C, Forés R, García-Marco JA, Ojeda E, Sanjuán I, Ruiz E, Krsnik I, Navarro B, Gil S, Magro E, de Laiglesia A, Gonzalo-Daganzo R, Martín-Donaire T, Rico M, Millán I, Fernández MN.*

Bone Marrow Transplant. 2009, 43(5):365-73.

### **Early Hematopoietic Recovery after Single Unit Unrelated Cord Blood Transplantation in Adults Supported by Co-Infusion of Mobilized Stem Cells from a Third Party Donor.**

*Magro E, Regidor C, Cabrera R, Sanjuan I, Fores R, García-Marco JA, Ruiz E, Gil S, Bautista G, Millan I, Madrigal A, Fernandez MN.*

Haematologica 2006, 91(5):640-8.

### **Umbilical-Cord Blood for Transplantation in Adults.**

*Fernandez MN, Regidor C, Cabrera R.*

New Engl J Med. 2005, 352(9):935-7.

### **Unrelated Umbilical Cord Blood Transplants in Adults: Early Recovery of Neutrophils by Supportive Co-Transplantation of a Low Number of Highly Purified Peripheral Blood CD34<sup>+</sup> Cells from an HLA-Haploidentical Donor.**

*Fernandez MN, Regidor C, Cabrera R, Garcia-Marco JA, Fores R, Sanjuan I, Gayoso J, Gil S, Ruiz E, Little AM, McWhinnie A, Madrigal A.*

Exp Hematol. 2003, 31(6):535-44.

### **Simultaneous Cord Blood Transplantation of ex vivo Expanded Cells for High Risk Leukemia.**

*Kögler G, Nürnberger W, Fischer J, Niehues T, Somville T, Göbel U, Wernet P.*

Bone Marrow Transplant. 1999, 24(4):397-403.

## Tumor Cell Purging in Autologous Transplantation

### **CD34<sup>+</sup> Selected versus Unselected Autologous Stem Cell Transplantation in Patients with Advanced-Stage Mantle Cell and Diffuse Large B-Cell Lymphoma.**

Berger MD, Branger G, Leibundgut K, Baerlocher GM, Seipel K, Mueller BU, Gregor M, Ruefer A, Pabst T.

Leuk Res. 2015, 39(6):561-7.

### **Influence of ex vivo Purging with CliniMACS CD34<sup>+</sup> Selection on Outcome after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma.**

Yahng SA, Yoon JH, Shin SH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Kim DW, Lee JW, Min WS, Park CW, Kim Y, Cho SG.

Br J Haematol. 2014, 164(4):555-64.

### **CD34<sup>+</sup> Immunoselection of Autologous Grafts for the Treatment of High-Risk Neuroblastoma.**

Marabelle A, Merlin E, Halle P, Paillard C, Berger M, Tchirkov A, Rousseau R, Leverger G, Piguat C, Stephan JL, Demeocq F, Kanold J.

Pediatr Blood Cancer. 2011, 56(1):134-42.

### **Autologous Stem Cell Transplantation with Selected CD34<sup>+</sup> Cells and Unmanipulated Peripheral Blood Stem Cells in Patients with Relapsed and Refractory Hodgkin's Lymphoma: A Single Centre Experience.**

Ballova V, Ladicka M, Vranovsky A, Lakota J.

Neoplasma 2008, 55(5):428-36.

### **Infections after CD34-Selected or Unmanipulated Autologous Hematopoietic Stem Cell Transplantation.**

Frère P, Pereira M, Fillet G, Beguin Y.

Eur J Haematol. 2006, 76(2):102-8.

### **Immunologic Purging of Autologous Peripheral Blood Stem Cell Products based on CD34 and CD133 Expression can be Effectively and Safely Applied in Half of the Acute Myeloid Leukemia Patients.**

Feller N, van der Pol MA, Waaijman T, Weijers GW, Westra G, Ossenkuppele GJ, Schuurhuis GJ.

Clin Cancer Res. 2005, 11(13):4793-801.

### **Isolation and Transplantation of Highly Purified Autologous Peripheral CD34<sup>+</sup> Progenitor Cells: Purging Efficacy, Hematopoietic Reconstitution in Non-Hodgkin's Lymphoma (NHL): Results of Japanese Phase II Study.**

Imai Y, Chou T, Tobinai K, Tanosaki R, Morishima Y, Ogura M, Shimazaki C, Taniwaki M, Hiraoka A, Tanimoto M, Koike T, Kogawa K, Hirai H, Yoshida T, Tamura K, Kishi K, Hotta T; CliniMACS Study Group.

Bone Marrow Transplant. 2005, 35(5):479-87.

### **Rituximab in vivo Purging is Safe and Effective in Combination with CD34-Positive Selected Autologous Stem Cell Transplantation for Salvage Therapy in B-NHL.**

Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T, Huber C, Dergis HG.

Bone Marrow Transplant. 2002, 29(9):769-75.

### **Isolation and Transplantation of Highly Purified Autologous Peripheral CD34<sup>+</sup> Progenitor Cells: Purging Efficacy, Hematopoietic Reconstitution and Long-Term Outcome in Children with High Risk Neuroblastoma.**

Handgretinger R, Lang P, Ihm K, Schumm M, Geiselhart A, Koscielniak E, Hero B, Klingebiel T, Niethammer D.

Bone Marrow Transplant. 2002, 29(9):731-6.

### **Improving Outcomes in Autologous Transplantation for Patients with Follicular and Mantle Cell Lymphoma.**

Brugger W.

Semin Oncol. 2002, 29(2, S6):23-6.

### **Highly Purified CD34<sup>+</sup> Cells Isolated Using Magnetically Activated Cell Selection Provide Rapid Engraftment Following High-Dose Chemotherapy in Breast Cancer Patients.**

Richel D, Johnsen HE, Canon J, Guillaume T, Schaafsma MR, Schenkeveld C, Hansen SW, McNiece I, Gringeri AJ, Briddell R, Ewen C, Davies R, Freeman J, Miltenyi S, Symann M.

Bone Marrow Transplant. 2000, 25(3):243-9.

### **CD34<sup>+</sup> Cell Enrichment for Autologous Peripheral Blood Stem Cell Transplantation by Use of the CliniMACS Device.**

Després D, Flohr TA, Uppenkamp M, Baldus M, Hoffmann M, Huber C, Dergis HG.

J Hematother Stem Cell Res. 2000, 9(4):557-64.

## Autologous Transplantation (i.a. Autoimmune Diseases)

### **Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.**

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St. Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE, for the SCOT Study Investigators.  
N Engl J Med. 2018, 378(1):35-47.

### **Does ex vivo CD34<sup>+</sup> Positive Selection Influence Outcome after Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients?**

Oliveira MC, Labopin M, Henes J, Moore J, Del Papa N, Cras A, Sakellari I, Schroers R, Scherer HU, Cuneo A, Kyrzcz-Krzemien S, Daikeler T, Alexander T, Finke J, Badoglio M, Simoes B, Snowden JA, Farge D, for EBMT Autoimmune Diseases Working Party.  
Bone Marrow Transplant. 2017, 51(4):501-5.

### **Manufacture of Autologous CD34<sup>+</sup> Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases.**

Keever-Taylor CA, Heimfeld S, Steinmiller KC, Nash RA, Sullivan KM, Czarniecki CW, Granderson TC, Goldstein JS, Griffith LM.  
Biol Blood Marrow Tr. 2017, 23(9):1463-72.

### **Immunoablation and Autologous Haematopoietic Stem-Cell Transplantation for Aggressive Multiple Sclerosis: A Multicentre Single-Group Phase 2 Trial.**

Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Brucker I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneville P, Lapiere Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, Freedman MS.  
Lancet. 2016, 388(10044):576-85.

### **Intravitreal Autologous Bone Marrow CD34<sup>+</sup> Cell Therapy for Ischemic and Degenerative Retinal Disorders: Preliminary Phase 1 Clinical Trial Findings.**

Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, Zawadzki RJ, Werner JS, Nolta J.  
Invest Ophthalmol Vis Sci. 2015, 56(1):81-9.

### **Local Transplantation of Granulocyte Colony Stimulating Factor-Mobilized CD34<sup>+</sup> Cells for Patients with Femoral and Tibial Nonunion: Pilot Clinical Trial.**

Kuroda R, Matsumoto T, Niikura T, Kawakami Y, Fukui T, Lee SY, Mifune Y, Kawamata S, Fukushima M, Ashara T, Kawamoto A, Kurosaka M.  
Stem Cells Transl Med. 2014, 3(1):128-34.

### **Intracerebral Implantation of autologous Peripheral Blood Stem Cells in Stroke Patients: A Randomized Phase II Study.**

Chen DC, Lin SZ, Fan JR, Lin CH, Lee W, Lin CC, Liu YJ, Tsai CH, Chen JC, Cho DY, Lee CC, Shyu WC.  
Cell Transpl. 2014, 23(12):1599-612.

### **Autologous Haematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus: Data from the European Group for Blood and Marrow Transplantation registry.**

Alchi B, Jayne D, Labopin M, Demin A, Sergeevicheva V, Alexander T, Gualandi F, Gruhn B, Ouyang J, Rzepecki P, Held G, Sampol A, Voswinkel J, Ljungman P, Fassas A, Badoglio M, Saccardi R, Farge D, and on behalf of the EBMT Autoimmune Disease Working Party members.  
Lupus. 2013, 22(3):245-53.

### **Optimization of Autologous Stem Cell Transplantation for Systemic Sclerosis – A Single-Center Longterm Experience in 26 Patients with Severe Organ Manifestations.**

Henes JC, Schmalzing M, Vogel W, Riemekasten G, Fend F, Kanz L, Koetter I.  
J Rheumatol. 2012, 39(2):269-75.

### **Remission of Refractory Crohn's Disease by High-Dose Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation.**

Hasselblatt P, Drognitz K, Potthoff K, Bertz H, Kruis W, Schmidt C, Stallmach A, Schmitt-Graeff A, Finke J, Kreisel W.  
Aliment Pharmacol Ther. 2012, 36(8):725-35.

### **Depletion of Autoreactive Immunological Memory Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients with Refractory SLE Induces Long-Term Remission through de novo Generation of a Juvenile and Tolerant Immune System.**

Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, Mei H, Radtke H, Gromnica-Ihle E, Burmester GR, Arnold R, Radbruch A, Hiepe F.  
Blood 2009, 113(1):214-23.

### **Long-Term Follow-Up Results after Autologous Haematopoietic Stem Cell Transplantation for Severe Systemic Sclerosis.**

Vonk MC, Marjanovic Z, van den Hoogen FH, Zohar S, Schattenberg AV, Fibbe WE, Larghero J, Gluckman E, Preijers FW, van Dijk AP, Bax JJ, Roblot P, van Riel PL, van Laar JM, Farge D.  
Ann Rheum Dis. 2008, 67(1):98-104.

**Autologous Stem Cell Transplantation in Children with Severe Progressive Systemic or Polyarticular Juvenile Idiopathic Arthritis.**

*Brinkman DMC, de Kleer IM, ten Cate R, van Rossum MAJ, Bekkering WP, Fasth A, van Tol MJD, Kuis W, Wulffraat NM, Vossen JM.*  
Arthritis Rheumatol. 2007, 56(7):2410-21.

**Autologous Stem Cell Transplantation of Treatment-Resistant Systemic Vasculitis – A Single Center Experience and Review of the Literature.**

*Kotter I, Daikeler T, Amberger C, Tyndall A, Kanz L.*  
Clin Nephrol. 2005, 64(6):485-9.

**Autologous Stem Cell Transplantation in the Treatment of Systemic Sclerosis: Report from the EBMT/EULAR Registry.**

*Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, Peter HH, Breedveld FC, Fibbe WE, Black C, Denton C, Koetter I, Locatelli F, Martini A, Schattenberg AVN, van den Hoogen F, van de Putte L, Lanza F, Arnold R, Bacon PA, Bingham S, Ciceri F, Didier B, Diez-Martin JL, Emery P, Feremans W, Hertenstein B, Hiepe F, Luosujärvi R, Leon Lara A, Marmont A, Martinez AM, Pascual Cascon H, Bocelli-Tyndall C, Bluckman E, Gratwohl A, Tyndall A.*  
Ann Rheum Dis. 2004, 63(8):974-81.

**CD34<sup>+</sup> Selected Autologous Peripheral Blood Stem Cell Transplantation for Multiple Sclerosis: Report of Toxicity and Treatment Results at One Year of Follow-Up in 15 Patients.**

*Carreras E, Saiz A, Marin P, Martinez C, Rovira M, Villamor N, Aymerich M, Lozano M, Fernandez-Aviles F, Urbano-Ispizua A, Montserrat E, Graus F.*  
Haematologica. 2003, 88(3):306-14.

**Autologous Stem Cell Transplantation in Refractory Autoimmune Diseases after *in vivo* Immunoablation and *ex vivo* Depletion of Mononuclear Cells.**

*Rosen O, Thiel A, Massenkeil G, Hiepe F, Häupl T, Radtke H, Burmester GR, Gromnica-Ihle E, Radbruch A, Arnold R.*  
Arthritis Res. 2000, 2(4):327-36.

## CliniMACS® Selection Performance

***Ex vivo* T-Cell Depletion in Allogeneic Hematopoietic Stem Cell Transplant: Past, Present and Future.**

*Saad A and Lamb LS.*  
Bone Marrow Transplant. 2017, 52(9):1241-8.

**Results of Using Automated CliniMACS Prodigy for CD34 Selection from Mobilized Peripheral Blood Stem Cell Products.**

*Bateman CM, Antonenas V, Yehson K, Tong D, Hansra G, Clancy LE, Shaw PJ, Micklethwaite KP, Gottlieb D.*  
Blood 2017, 130(S1):3201.

**Assessment of Stability of CD34<sup>+</sup> Cell Products Enriched by Immunoselection from Peripheral Blood Mononuclear Cells during Refrigerated Storage.**

*Krasna M, Malicev E, Rozman JZ, Vrtovec B.*  
Transfus Apher Sci. 2017, 56(4):566-70.

**How do I Perform Hematopoietic Progenitor Cell Selection?**

*Avecilla ST, Goss C, Bleau S, Tonon JA, Meagher RC.*  
Transfusion 2016, 56(5):1008-12.

**Preliminary Evaluation of a Highly Automated Instrument for the Selection of CD34<sup>+</sup> Cells from Mobilized Peripheral Blood Stem Cell Concentrates.**

*Stroncek DF, Tran M, Frodigh SE, David-Ocampo V, Ren J, Larochele A, Sheikh V, Sereti I, Miller JL, Longin K, Sabatino M.*  
Transfusion 2016, 56(2):511-7.

**Automation of Cellular Therapy Product Manufacturing: Results of a Split Validation Comparing CD34 Selection of Peripheral Blood Stem Cell Apheresis Product with a Semi-Manual vs. an Automatic Procedure.**

*Hümmer C, Poppe C, Bunos M, Stock B, Wingefeld E, Huppert V, Stuth J, Reck K, Essl M, Seifried E, Bonig H.*  
Transl Med. 2016, 14(1):76.

**Automated CD34 Cell Isolation of Peripheral Blood Stem Cell Apheresis Product.**

*Spohn G, Wiercinska E, Karpova D, Bunos M, Hümmer C, Wingefeld E, Sorg N, Poppe C, Huppert V, Stuth J, Reck K, Essl M, Seifried E, Bönig H.*  
Cytotherapy 2015, 17(10):1465-71.

**Optimization of the Immunomagnetic Selection in Microcythemic Donors Enrolled for Haploidentical Transplantation.**

*Scerpa MC, Daniele N, Rossi C, Ciammetti C, Sodani P, Lanti A, Adorno G, Lucarelli G, Isacchi G, Zinno F.*  
Transfus Apher Sci. 2013, 48(2):263-9.

**Improved Immunomagnetic Enrichment of CD34<sup>+</sup> Cells from Umbilical Cord Blood Using the CliniMACS Cell Separation System.**

*Blake JM, Nicoud IB, Weber D, Voorhies H, Guthrie KA, Heimfeld S, and Delaney C.*  
Cytotherapy 2012, 14(7):818-22.

**HLA-Haploidentical Transplantations for Primary Immunodeficiencies: A Single-Center Experience.**

*Cipe FE, Dogu F, Aytekin C, Yuksek M, Kendirli T, Yildiran A, Bozdogan G, Karatas D, Reisli I, Dalva K, Arpacı F, and İkinciogulları A.*  
Pediatr Transplant. 2012, 16(5):451-7.

**Characteristics of CliniMACS<sup>®</sup> System CD34-Enriched T Cell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia - Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303.**

*Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ.*  
Biol Blood Marrow Tr. 2012, 18(5):690-7.

**Evaluation of More Than 500 CD34 Selection Procedures on PBSC Products Using the CliniMACS.**

*Slaper-Cortenbach I, Voermans C, Schuurhuis G, Preijers F, Theunissen K, van Riet I, Dohmen S, Braakman E.*  
Cytotherapy 2005, 7(1):82a.

**Graft Engineering for Allogeneic Haploidentical Stem Cell Transplantation.**

*Tabilio A, Falzetti F, Zei T, De Ioanni M, Bonifacio E, Battelli F, Iacucci Ostini R, Ballanti S, Cimminiello M, Capponi M, Silvani C, Minelli O, Fettucciari K, Marconi P, Rosati E, Santucci A, Di Ianni M, Aversa F, Martelli MF.*  
Blood Cells Mol Dis. 2004, 33(3):274-80.

**CD34<sup>+</sup> Cell Selection of Peripheral Blood Progenitor Cells Using the CliniMACS Device for Allogeneic Transplantation: Clinical Results in 102 Patients.**

*Ringhoffer M, Wiesneth M, Harsdorf S, Schlenk RF, Schmitt A, Reinhardt PP, Moessner M, Grimminger W, Mertens T, Reske SN, Dohner H, Bunjes D.*  
Br J Haematol. 2004, 126(4):527-35.

**Clinical-Grade Cell Purification from Thawed Cord Blood: An Example of Translational Research.**

*Giordano R, Lazzari L, Montemurro T, Lecchi L, Porretti L, Rebullà P.*  
Bone Marrow Transplant. 2003, 32(9):965-6.

**Comparison of Two Different Methods for CD34<sup>+</sup> Selection and T Cell Depletion in Peripheral Blood Stem Cell Grafts – Our Experiences with CellPro, E rosetting and CliniMACS Technique.**

*Polouckova A, Vodvarkova A, Kobylka P, Hrubá A, Gasova Z, Marinov I, Fales I, Sedlacek P, Kozak T, Stary J.*  
Neoplasma 2001, 48(5):374-81.

**Isolation of Highly Purified Autologous and Allogeneic Peripheral CD34<sup>+</sup> Cells Using the CliniMACS Device.**

*Schumm M, Lang P, Taylor G, Kuci S, Klingebiel T, Bühring HJ, Geiselhart A, Niethammer D, Handgretinger R.*  
J Hematother Stem Cell Res. 1999, 8(2):209-18.



Miltenyi Biotec provides products and services worldwide.

Visit [www.miltenyibiotec.com/local](http://www.miltenyibiotec.com/local) to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients.

The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells.

Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE).

CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, MACS, and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Copyright © 2019 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.